NASDAQ:BIIB

Biogen (BIIB) Stock Forecast, Price & News

$303.67

+7.26 (+2.45%)

(As of 02:51 PM ET)

Compare

Today's Range: $300.19
▼
$308.38
50-Day Range: $265.17
▼
$318.06
52-Week Range: $188.54
▼
$319.74

Volume: 656,785 shs
Average Volume: 970,447 shs
Market Capitalization: $43.95 billion

P/E Ratio: 14.10
Dividend Yield: N/A
Price Target: $328.38

Biogen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.81 Rating Score
Upside/Downside: 8.4% Upside
$328.92 Price Target
Short Interest: Healthy
2.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.89
Upright™ Environmental Score
News Sentiment: 0.43
Based on 12 Articles This Week
Insider Trading: Selling Shares
$982,911 Sold Last Quarter
Proj. Earnings Growth: 5.78%
From $15.40 to $16.29 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

287th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

45th out of 330 stocks

2.4

Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Buy. The company's average rating score is 2.81, and is based on 21 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $328.92, Biogen has a forecasted upside of 8.4% from its current price of $303.54.
Amount of Analyst Coverage
Biogen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.06% of the float of Biogen has been sold short.
Short Interest Ratio / Days to Cover
Biogen has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biogen has recently increased by 30.40%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Biogen has received a 46.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dimethyl fumarate ", "Natalizumab", and "Rituximab" products. See details.
Environmental Sustainability
The Environmental Impact score for Biogen is -1.89.

1.9

News and Social Media Coverage

News Sentiment
Biogen has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Biogen this week, compared to 15 articles on an average week.
Search Interest
Only 14 people have searched for BIIB on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.
MarketBeat Follows
7 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $982,911.00 in company stock.
Percentage Held by Insiders
Only 0.65% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
84.40% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to grow by 5.78% in the coming year, from $15.40 to $16.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 14.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.68.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 14.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 95.71.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 2.48. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (BIIB)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

June 1, 2023 | reuters.com

Medicare to broaden coverage for new Alzheimer's drugs after full approval

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

June 1, 2023 | msn.com

Piper Sandler Maintains Biogen (BIIB) Overweight Recommendation

June 1, 2023 | markets.businessinsider.com

Goldman Sachs Remains a Buy on Biogen (BIIB)

June 1, 2023 | markets.businessinsider.com

Biogen (BIIB) Receives a Buy from Mizuho Securities

June 1, 2023 | finance.yahoo.com

Medicare Will Pay for Biogen’s Alzheimer’s Drug, With a Caveat

June 1, 2023 | finance.yahoo.com

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

May 29, 2023 | finance.yahoo.com

Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company

May 26, 2023 | msn.com

Biogen Unusual Options Activity For May 26

May 26, 2023 | finance.yahoo.com

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

May 25, 2023 | finance.yahoo.com

Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?

May 23, 2023 | msn.com

Analyst Ratings for Biogen

May 23, 2023 | msn.com

Wedbush Reiterates Biogen (BIIB) Neutral Recommendation

May 23, 2023 | bizjournals.com

Alzheimer's patient advocates to rally to expand drug access

May 22, 2023 | finance.yahoo.com

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

May 22, 2023 | americanbankingnews.com

Financial Analysis: Biogen (NASDAQ:BIIB) versus Revolution Medicines (NASDAQ:RVMD)

May 19, 2023 | msn.com

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today

May 19, 2023 | finance.yahoo.com

1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market

May 18, 2023 | bizjournals.com

Biogen Alzheimer's drug could cost Medicare $5B a year

May 18, 2023 | finance.yahoo.com

Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 29% Above Its Share Price

May 18, 2023 | americanbankingnews.com

Biogen (NASDAQ:BIIB) Receives New Coverage from Analysts at StockNews.com

May 16, 2023 | americanbankingnews.com

Short Interest in Biogen Inc. (NASDAQ:BIIB) Grows By 13.5%

May 16, 2023 | benzinga.com

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

May 16, 2023 | finanznachrichten.de

Biogen Inc.: Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

May 16, 2023 | markets.businessinsider.com

Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease

See More Headlines

BIIB Price History

30 days | 90 days | 365 days | Advanced Chart

BIIB Company Calendar

Last Earnings: 4/25/2023
Today: 6/01/2023
Next Earnings (Estimated): 7/19/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BIIB
CUSIP: 09062X10
CIK: 875045
Web: www.biogen.com
Phone: (617) 679-2000
Fax: 617-679-2617
Employees: 8,725
Year Founded: 1978

Price Target and Rating

Average Stock Price Forecast: $328.92
High Stock Price Forecast: $371.00
Low Stock Price Forecast: $263.00
Forecasted Upside/Downside: +8.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.81
Research Coverage: 26 Analysts

Profitability

EPS (Most Recent Fiscal Year): $21.54
Trailing P/E Ratio: 14.10
Forward P/E Ratio: 19.72
P/E Growth: 2.48
Net Income: $3.05 billion
Net Margins: 30.99%
Pretax Margin: 36.45%
Return on Equity: 19.60%
Return on Assets: 10.25%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 3.24
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: $10.17 billion
Price / Sales: 4.32
Cash Flow: $21.88 per share
Price / Cash Flow: 13.88
Book Value: $95.25 per share
Price / Book: 3.19

Miscellaneous

Outstanding Shares: 144,740,000
Free Float: 143,801,000
Market Cap: $43.95 billion
Optionable: Optionable
Beta: 0.19

Social Links

Key Executives

Christopher A. Viehbacher
President, Chief Executive Officer & Director

Nicole Murphy
Head-Pharmaceutical Operations & Technology

Michael R. McDonnell
Chief Financial Officer & Executive Vice President

Mahalakshmi Radhakrishnan
Chief Medical Officer & Group Senior VP

Priya Singhal
Executive VP, Head-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?: 26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.
What is Biogen's stock price forecast for 2023?: 26 brokerages have issued 1-year price targets for Biogen's stock. Their BIIB share price forecasts range from $263.00 to $371.00. On average, they anticipate the company's share price to reach $328.38 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.
How have BIIB shares performed in 2023?: Biogen's stock was trading at $276.92 at the start of the year. Since then, BIIB shares have increased by 7.0% and is now trading at $296.41.
View the best growth stocks for 2023 here.
Are investors shorting Biogen?: Biogen saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 30.4% from the April 30th total of 2,270,000 shares. Based on an average daily volume of 905,900 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the shares of the company are short sold.
View Biogen's Short Interest.
When is Biogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our BIIB earnings forecast.
How were Biogen's earnings last quarter?: Biogen Inc. (NASDAQ:BIIB) issued its quarterly earnings results on Tuesday, April, 25th. The biotechnology company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.25 by $0.15. The biotechnology company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 30.99% and a trailing twelve-month return on equity of 19.60%. The firm's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.62 EPS.
Read the conference call transcript.
What ETFs hold Biogen's stock?: ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), Horizon Kinetics Medical ETF (MEDX), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), iShares Neuroscience and Healthcare ETF (IBRN), Subversive Mental Health ETF (SANE), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).
What guidance has Biogen issued on next quarter's earnings?: Biogen issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $15.00-$16.00 for the period, compared to the consensus earnings per share estimate of $15.48. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?: 394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.
What other stocks do shareholders of Biogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).
What is Biogen's stock symbol?: Biogen trades on the NASDAQ under the ticker symbol "BIIB."
Who are Biogen's major shareholders?: Biogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.66%), State Street Corp (4.67%), Wellington Management Group LLP (3.77%), Geode Capital Management LLC (2.14%), Envestnet Asset Management Inc. (1.77%) and Price T Rowe Associates Inc. MD (1.44%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends.
How do I buy shares of Biogen?: Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biogen's stock price today?: One share of BIIB stock can currently be purchased for approximately $296.41.
How much money does Biogen make?: Biogen (NASDAQ:BIIB) has a market capitalization of $42.90 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $21.54 on an earnings per share basis.
How many employees does Biogen have?: The company employs 8,725 workers across the globe.
Does Biogen have any subsidiaries?: The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?: Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial